Morgan Stanley lowered the firm’s price target on Avantor (AVTR) to $25 from $27 and keeps an Overweight rating on the shares after Q4 results were in line, led by bioprocessing upside, and Avantor returned to organic growth. FY25 guidance points to 1%-3% organic growth and double-digit EPS growth excluding the Clinical Service divestiture, which the firm calls “prudent underlying assumptions” that leave room for upside if end markets recover. The selloff post-earnings “appears overdone,” the analyst added.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AVTR:
- Avantor price target lowered to $22 from $24.50 at Bernstein
- Balanced Outlook on Avantor: Hold Rating Amidst Segment Underperformance and Strong Expense Management
- Favorable Risk-Reward Profile and Organic Growth Drive Buy Rating for Avantor
- Avantor price target lowered to $23 from $26 at Barclays
- Avantor Reports 2024 Financial Results, Shows Growth Potential